Metabolomic Study for Localized Prostate Cancer

• Conditions: Prostate Cancer

• Registration Number: NCT01968538
• Lead Sponsor: Georgetown University

Brief Summary

Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances in omic analysis may offer additional information to the physician about prognosis and radiation response. We propose to establish a protocol to incorporate omic analysis into the evaluation and treatment of patients with prostate cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Study First Submitted: 2013-09-19
• Study First Submitted QC: 2013-10-18
• Study First Posted: 2013-10-24
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-27
• Last Update Posted: 2023-02-28
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: Male
• Target Recruitment: 400

Inclusion Criteria

• Males who are older than 18 years old,
• with clinically localized prostate cancer
• are receiving radiation therapy

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
molecular changes in biofluid	5 years

Trial Locations

Locations (1)

Georgetown University Hospital; 🇺🇸 Arlington, Virginia, United States